ArticleJournal of inflammation research2026
Prognostic Value of the Postoperative Advanced Lung Cancer Inflammation Index in Patients with Prostate Cancer Undergoing Radical Prostatectomy.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigated whether the postoperative advanced lung cancer inflammation index (ALI) has prognostic significance in patients with prostate cancer who underwent radical prostatectomy. It also explored the potential role of ALI as a biomarker for assessing postoperative recurrence risk. Patients and Methods: This retrospective, single-center study included 425 patients with localized or selected locally advanced prostate cancer who underwent radical prostatectomy at the First Affiliated Hospital of Chengdu Medical College. Postoperative ALI was calculated using clinical and laboratory data obtained at the first follow-up visit, approximately three months after surgery. Patients were categorized into low- and high-ALI groups according to the optimal ALI cut-off value. Associations between postoperative ALI and overall survival and biochemical recurrence-free survival were evaluated using Kaplan-Meier analysis, Cox proportional hazards regression, and propensity score matching. The median follow-up duration was 56 months, 38 patients dead, and 156 patients had biochemical recurrences at the end of follow-up. Results: A low postoperative ALI was significantly associated with a lower body mass index (p = 0.001), higher Gleason scores (p = 0.0036), elevated preoperative prostate-specific antigen levels (p < 0.0001), more advanced pathological T stage (p < 0.0001), and a greater frequency of lymph-node metastasis (p = 0.002). Kaplan-Meier survival curves demonstrated that patients in the low-ALI group experienced worse survival outcomes, including reduced overall survival (HR = 3.32; 95% CI, 2.41-5.87; p = 0.012) and shorter biochemical recurrence-free survival (HR = 2.57; 95% CI, 1.58-3.65; p = 0.002), compared with those in the high-ALI group. In multivariable Cox regression models, ALI remained an independent predictor of both overall survival (p < 0.0001) and biochemical recurrence-free survival (p < 0.0001) after adjustment of confounding factors. Conclusion: Among patients with prostate cancer undergoing radical prostatectomy, a low postoperative ALI was associated with shorter overall survival and biochemical recurrence-free survival compared with a high postoperative ALI. These findings suggest that postoperative ALI may provide prognostic information in patients undergoing radical prostatectomy; however, its clinical utility requires confirmation through prospective, multicenter studies and external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.